/
BTAI
$1.40+$0.09 (+6.87%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$40.4M
31M shares
52-week range
$1.01 – $8.08
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
5.73%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-456.36
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $375.0K | $1.4M | $2.3M | $642.0K |
| Cost of revenue | $17.0K | $156.0K | $0 | $0 | $20.0K | $1.3M | $2.1M | $164.0K |
| Gross profit | −$17.0K | −$156.0K | $0 | $0 | $355.0K | $120.0K | $123.0K | $478.0K |
| Gross margin | — | — | — | — | 94.7% | 8.7% | 5.4% | 74.5% |
| R&D | $14.6M | $25.8M | $58.5M | $52.7M | $91.2M | $84.3M | $30.4M | $30.3M |
| Operating income | −$20.0M | −$33.6M | −$82.3M | −$106.9M | −$159.6M | −$171.8M | −$67.2M | −$50.3M |
| EBITDA | −$19.3M | −$32.8M | −$82.1M | −$106.6M | −$157.2M | −$165.4M | −$44.2M | −$52.6M |
| Net income | −$19.3M | −$32.3M | −$82.2M | −$106.9M | −$165.8M | −$179.1M | −$59.6M | −$69.9M |
| Net margin | — | — | — | — | -44201.9% | -12974.9% | -2630.1% | -10887.4% |
| EPS (diluted) | -21.16 | -32.38 | -60.63 | -64.87 | -94.67 | -98.35 | -23.51 | -5.73 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.67 | $-2.11–$-1.22 | 1 |
| 2027 | $19M | $-1.53 | $-1.98–$-1.08 | 2 |
| 2028 | $63M | $-0.79 | $-1.24–$-0.26 | 1 |
| 2029 | $179M | $-0.62 | $-0.98–$-0.21 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BioXcel Therapeutics, Inc. Common Stock
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
www.bioxceltherapeutics.com- Employees
- 29
- IPO / List date
- Mar 8, 2018
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds BTAI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BTAI as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-02-10 | 1-for-16reverse |
Recent trades on TradeandTell
No one on the platform has traded BTAI yet.
